CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
MP-424 (Telaprevir)drug
Likely dose
MP-424 (Telaprevir) 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00591214
NCT00591214Phase 1Completed
CompareCT.gov

A Phase I, Open-Label, Single-Dose Study of MP-424 in Patients With Genotype 1b Hepatitis C

Tanabe Pharma Corporation·interventional·Posted Jan 11, 2008·Updated Jan 6, 2026

In Brief

A Phase 1 clinical trial evaluating MP-424 (Telaprevir) for Chronic Hepatitis C. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesJapan
CollaboratorsVertex Pharmaceuticals Incorporated

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2008
Enrollment StartDec 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.5 years ago

Interventions

MP-424 (Telaprevir)drug

Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)